Delivery Order SPE2DB22D2007-SPE2DB25FJ3CN
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector units valued at $6,165.34, with a completion deadline of July 23, 2025. This firm fixed-price, competitively awarded delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. Benlysta (belimumab) is a monoclonal antibody therapy used to treat systemic lupus erythematosus, and the auto-injector formulation facilitates...
- The Defense Logistics Agency awarded a $6,165.34 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector units. The contract, issued on July 22, 2025, with an ultimate completion date of August 12, 2025, represents a non-set-aside competitive award. Performance will be executed from the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen Drug Corp's larger Indefinite...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $55,488.06 for Benlysta 200 mg/ml auto-injectors on September 17, 2025, with an ultimate completion date of October 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order valued at $6,165.34 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on July 31, 2025, with an ultimate completion date of August 21, 2025. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract utilizing AmerisourceBergen's established indefinite delivery contract vehicle with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive global pharmaceutical support...
- The Defense Logistics Agency awarded a delivery order valued at $3,082.67 to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/ml auto-injector on August 5, 2025, with completion targeted for August 26, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement utilizing the company's existing Indefinite Delivery Contract vehicle. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, supporting federal...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $3,082.67 for Benlysta 200 mg/ml auto-injectors on August 19, 2025, with completion scheduled for September 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other autoimmune...
- The Defense Logistics Agency awarded a $6,165.34 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injectors, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Benlysta (belimumab) is a monoclonal antibody used to treat...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on September 10, 2025, with an ultimate completion date of October 1, 2025. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $6,165.34 and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and is supplied via auto-injector,...
- The Defense Logistics Agency awarded a delivery order valued at $6,165.34 to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/mL auto-injectors. The award, made on September 9, 2025, represents a firm fixed-price delivery order with an ultimate completion date of September 30, 2025. This non-set-aside contract was competitively awarded and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's headquarters. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $9,248.01 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on September 8, 2025, with an ultimate completion date of September 29, 2025. This is a firm fixed price delivery order with no set-aside designation, placing performance at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a competitively awarded transaction under AmerisourceBergen's broader pharmaceutical...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ3CNDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,165.34 to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/mL auto-injectors. The contract, awarded on July 18, 2025, with an ultimate completion date of August 8, 2025, utilizes firm fixed pricing with no set-aside designation. This delivery order represents a competitive award under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a total value of $999,999,999.00 and extends through December 2026. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta (belimumab) is a monoclonal antibody used to treat systemic lupus erythematosus and other autoimmune conditions, and its delivery through auto-injector devices enhances patient accessibility and ease of administration. AmerisourceBergen's role as a prime pharmaceutical distributor for the DLA Medical Supply Chain positions it to fulfill critical pharmaceutical needs across military healthcare systems, the Defense Health Agency, and other federal healthcare organizations. This delivery order exemplifies the company's capacity to supply specialized biologic medications and medical devices to support military personnel and veteran healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.2k | 7/18/25 |